These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22378260)
21. Pharmaceutical pipeline. Lowen T Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279 [No Abstract] [Full Text] [Related]
22. Paul Brown. Interview by Asher Mullard. Brown P Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279 [No Abstract] [Full Text] [Related]
23. Paul Stoffels. Interview by Asher Mullard. Stoffels P Nat Rev Drug Discov; 2013 Apr; 12(4):258. PubMed ID: 23535929 [No Abstract] [Full Text] [Related]
24. Q&A: Bernard Munos. Bender E Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392 [No Abstract] [Full Text] [Related]
25. Large drug firms narrow their therapeutic interests. Mullard A Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171 [No Abstract] [Full Text] [Related]
26. Pfizer's home remedy. Abkowitz A Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588 [No Abstract] [Full Text] [Related]
27. Garry Neil. Interview by Asher Mullard. Neil G Nat Rev Drug Discov; 2012 Nov; 11(11):826. PubMed ID: 23123934 [No Abstract] [Full Text] [Related]
28. An audience with...John Reed. Reed J; Mullard A Nat Rev Drug Discov; 2014 Mar; 13(3):170-1. PubMed ID: 24577393 [No Abstract] [Full Text] [Related]
29. Virtual drug discovery with the rise of Chinese CROs. Zhang MQ Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343 [No Abstract] [Full Text] [Related]
30. An audience with... Nic Jones. Interview by Asher Mullard. Jones N Nat Rev Drug Discov; 2011 Apr; 10(4):252. PubMed ID: 21455228 [No Abstract] [Full Text] [Related]
31. Charles Hugh-Jones. Interview by Asher Mullard. Hugh-Jones C Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774 [No Abstract] [Full Text] [Related]
32. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030 [TBL] [Abstract][Full Text] [Related]
33. European lead factory opens for business. Mullard A Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292 [No Abstract] [Full Text] [Related]
34. Joe selby. Interview by Asher Mullard. Selby J Nat Rev Drug Discov; 2011 Aug; 10(9):652. PubMed ID: 21878972 [No Abstract] [Full Text] [Related]
35. Precompetitive consortia in biomedicine--how are we doing? Mittleman B; Neil G; Cutcher-Gershenfeld J Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770 [No Abstract] [Full Text] [Related]
36. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies. King G Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969 [No Abstract] [Full Text] [Related]
37. [The Innovative Medicine Initiative (IMI)]. Bril A; Canet E Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588 [TBL] [Abstract][Full Text] [Related]
38. David Urdal. Interview with Asher Mullard. Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031 [No Abstract] [Full Text] [Related]
39. Stephen Frye. Interview by Asher Mullard. Frye S Nat Rev Drug Discov; 2012 Apr; 11(5):346. PubMed ID: 22495334 [No Abstract] [Full Text] [Related]
40. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]